ÎçÒ¹¸£Àû

Skip to content
ApplyGive

Other ways to search: |

Research

Current Studies - Recruitment is Open

Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) Study
Dr. Ebenezer Nyenwe, MD -ÌýPrincipal Investigator

Primary Inclusion (Eligibility) Criteria:

  • Men between the ages of 45-80 years
  • Low testosterone levels
  • History of heart attack, artery disease, or stroke
  • Not currently on any testosterone replacement

Contact: Mary Beth Houston (Study Coordinator), (901) 448 2676; mepps1@uthsc.edu

Ceramides and Sphingolipids as Predictors of Incident Dysglycemia
Dr. Samuel Dagogo-Jack, MD and Dr. Nawajes Mandal, PhD - Principal Investigators

Primary Inclusion (Eligibility) Criteria:Ìý

  • Men and women between ages 18-65 years
  • Overall healthy, with no history of major medical issues
  • No personal history of diabetes diagnosis
  • No family history of diabetes

Contact: Mary Beth Houston (Study Coordinator), (901) 448 2676; mepps1@uthsc.edu.Ìý

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal HyperplasiaÌý
Dr. Helmut Steinberg, MD - Principal Investigator

Primary Inclusion (Eligibility) Criteria:

  • You are a man or woman between the ages of 18 to 55 years old
  • You have a documented diagnosis of classic CAH due to 21-hydroxylase deficiency
  • You’ll have been on a stable daily dose of steroids (glucocorticoids or mineralocorticoid) prior to starting the trial.

*Other criteria will apply.

Contact: Avnisha A. Patel (Study Coordinator), 901.448.1105 ; apatel87@uthsc.edu
For more information, visit official study website:

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Dr. Helmut Steinberg, MD - Principal Investigator

Primary Inclusion (Eligibility) Criteria:

  • You are a man or woman between the ages of 18 to 55 years old
  • You have a documented diagnosis of classic CAH due to 21-hydroxylase deficiency
  • You’ll have been on a stable daily dose of steroids (glucocorticoids or mineralocorticoid) prior to starting the trial.

*Other criteria will apply.

Contact: Avnisha A. Patel (Study Coordinator), 901.448.1105 ; apatel87@uthsc.edu
For more information, visit official study website:

Current Studies - Recruitment is Closed

Recruitment is Closed

Diabetes Prevention Program Outcomes Study (DPPOS)
Samuel Dagogo-Jack, MD (PI); Faye Hampton, RN - Study Coordinator
Sponsor: NIH/NIDDK
Participants of all races who had Impaired Glucose Tolerance between the ages of 25 with no upper age limit with a BMI of >24
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: Phone: (901) 448-5290; ehampto5@uthsc.edu


Epidemiology of Diabetes Interventions and Complications Study (EDIC)
Sam Dagogo-Jack, MD, FRCP (PI); Christine S. Wigley R.N. - Study Coordinator
Sponsor: NIH
Division of Endocrinology, Diabetes, and Metabolism
Participants are type 1 diabetics from the Diabetes Control and Complications Trial (DCCT)
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-7942 E-mail: cwigley@uthsc.edu


Acute Macronutrient Effects on Potential Modulators of Vascular Function
Dr. Helmut Steinberg, MD - Principal Investigator
This is a pilot study with the purpose to assess how differences in food composition in meals affect changes in hormones, fat, sugar, and other substances in your blood.

Ìý

Completed Studies

CAROLINA Trial

Sam Dagogo-Jack, MD (PI); Helmut Steinberg, MD - Study Coordinator
Sponsor: Boehringer Ingelheim
Type of patients for recruitment: Type 2 diabetes, H/O cardiovascular disease (previous vascular disease or evidence of vascular related end-organ damage), age = 40 and =85 years, high risk of cardiovascular events, with HbA1c 6.5-8.5% (treatment naïve) or 6.5-7.5% (treated)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE)
Samuel Dagogo-Jack, MD (PI); James Ekwensi, MD - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Contact: (901) 448-2676, jekwensi@uthsc.edu

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)
Samuel Dagogo-Jack, MD (PI); Ibiye Owei, MBBS- Study Coordinator
Sponsor: NIH
Participants are healthy individuals with either one or both parents with type 2 diabetes, age group 18-65Ìý

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)
Helmut Steinberg, MD (PI); Amy Bell - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease

Trial to Assess Chelation Therapy 2 (TACT2)
Dr. Helmut Steinberg, MD - Principal Investigator
Primary Inclusion (Eligibility) Criteria:

For more information, visit official study website: .Ìý

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk (Amplitude-O)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have Type 2 Diabetes Mellitus (T2DM) with high cardiovascular risk.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function (SCORED)
Dr. Ebenezer Nyenwe, MD - Principal Investigator
Participants have type 2 diabetes, cardiovascular risk factors, and moderately impaired renal function.

Ìý

Pre-Diabetes Study